Vaxcyte SVP Elvia Cowan sells $1.6 million in company stock

Vaxcyte's Senior Vice President of Finance and Chief Accounting Officer, Elvia Cowan, divested 19,000 shares of the company's stock on October 5, 2026, in a transaction valued at approximately $1.65 million. This sale, executed under a pre-approved Rule 10b5-1 trading plan, came at a price of $86.74 per share. The company's stock currently sits at $71.38, a price that has fluctuated amid recent market volatility, despite a substantial year-over-year gain of 63%.

Prior to selling her shares, Cowan had acquired the same amount through stock option exercise, which was carried out at a price of $25.92 per share, resulting in a value of around $492,480. Following these actions, Cowan currently holds a total of 27,860 shares of Vaxcyte common stock and maintains beneficial ownership of 74,068 stock options, giving her the right to purchase an additional 74,068 shares.

Analysts note that Vaxcyte appears to be overvalued compared to its intrinsic value, yet the company boasts a robust balance sheet with a stronger cash position over its debt. Vaxcyte has also unveiled promising developments in its VAX-31 vaccine candidate, with the OPUS-1 trial meeting its primary endpoint and proving non-inferior to competing vaccines.

Industry players like BofA Securities have raised their price targets, with BofA setting a new target of $146 and Guggenheim raising it to $125. Despite these optimistic market reactions, other firms such as BofA have adjusted their targets downward due to revised timelines for the VAX-31 vaccine's launch, now anticipated for 2029.

Additionally, Vaxcyte has announced new executive appointments, including Luis Jodar as Chief Medical Officer and David McAvoy as Chief Legal Officer, and has adjusted its trial data release window to the end of October 2026.